DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Military Burn
  4. Research Highlights/News
  5. 2025 Military Burn Research Program

Military Burn

NEWS RELEASE

Released: April 3, 2025

Department of Defense
Defense Health Agency Research and Development -
Medical Research and Development Command
Congressionally Directed Medical Research Programs (CDMRP)
Military Burn Research Program
Anticipated Funding Opportunities for Fiscal Year 2025 (FY25)

The Full-Year Continuing Appropriations and Extensions Act of 2025 provides $650M in funding for the CDMRP. Congress provided further guidance for CDMRP program-level funding, including funding for the Military Burn Research Program (MBRP). The FY25 MBRP intends to support military-relevant burn research. The CDMRP is part of the Defense Health Agency Research and Development at the U.S. Army Medical Research and Development Command (USAMRDC) and is the program office managing these anticipated FY25 funding opportunities.

The MBRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY25 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY25 MBRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.

Applications submitted to the FY25 MBRP must address one or more of the following focus areas:

  • Development and/or validation of methods to prevent, triage, and/or treat cold injury.
  • Research to innovate best practices in the acute burn care continuum.
  • Development and/or validation of methods that can be used in austere environments to prevent, assess, and /or treat burn injury-related complications including:
    • Over/under fluid resuscitation
    • Endotheliopathy
    • Sepsis
    • Inhalation injuries
    • Fungal infections
    • Hypermetabolism
  • Early interventions that reduce long-term pain, neuropathy, and temperature dysregulation. Studies must provide preliminary evidence for long-term effectiveness.

Award Mechanism Eligibility Key Mechanism Elements Funding
Discovery Award

New for FY25! 		Investigators at all academic levels (or industry equivalent) are eligible to be named as PI.
  • Supports innovative, untested, groundbreaking research that provides new insights and explores early concepts in battlefield burn care that provides the foundation for future translational and/or clinical research.
  • Project may be exploratory, hypothesis-driven, or hypothesis-generating but must be novel and based on strong scientific rationale and a well-developed study design and plan of analysis.
  • Research should lay the groundwork for future avenues of scientific investigation or product development for burn care delivered in an austere, resource-limited, battlefield environment.
  • Inclusion of preliminary data is not required.
  • Non-interventional clinical research studies ALLOWED.
  • Clinical trials NOT ALLOWED.
  • Pre-application submission required; full application submission by invitation only.
  • Maximum funding of $200,000 for total costs (direct costs plus indirect costs).
  • Maximum period of performance is 2 years.
Patient-Centered Research Award Investigators at or above the level of Assistant Professor or an independent investigator within the biomedical industry are eligible to be named as PI.
  • Bridges the gap between research, practice, and policy by building a knowledge base that provides clinically useful findings about how interventions, clinical practices/guidelines, tools, and policies can be deployed to burn patients in an austere, resource-limited, battlefield environment at the point of need.
  • Supports clinical research or clinical trials.
  • Preclinical or animal research NOT ALLOWED.
  • Descriptive, observational, and experimental studies ALLOWED.
  • Preliminary data required.
  • Pre-application submission required; full application submission by invitation only.
  • Maximum funding of $1.7 million (M) for total costs (direct costs plus indirect costs).
  • Maximum period of performance is 2 years.
Technology/Therapeutic Development Award Investigators at or above the level of Assistant Professor or an independent investigator within the biomedical industry are eligible to be named as PI.
  • Supports the translation of promising preclinical findings into burn products for clinical application in an austere, resource-limited, battlefield environment.
  • Product-oriented (e.g., medical device, drug, or clinical practice guidelines involving a therapeutic or technology). The product(s) to be developed must be tangible or knowledge supporting the development of a tangible product.
  • Proof of concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established.
  • Preliminary data required.
  • Clinical research is NOT ALLOWED.
  • Pre-application submission required; full application submission by invitation only.
  • Maximum funding of $1.7M for total costs (direct costs plus indirect costs).
  • Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage at https://eBRAP.org. For more information about the MBRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

Point of Contact:
CDMRP Public Affairs
301-619-9783
dha.detrick.cdmrp.mbx.public-affairs@health.mil


Last updated Thursday, April 3, 2025